There is a clear evidence-ranked ladder of options, and starting conservative does not appear to cost satisfaction later.
The hormone-releasing IUD is the first-line option and can reduce blood loss substantially, working about as well by five years as going straight to major surgery, because women whose IUD does not work well enough can still move on to other treatments. Tranexamic acid, taken only on bleeding days, meaningfully reduces blood loss and roughly triples the odds of improvement compared with placebo. Anti-inflammatory painkillers and combined hormonal contraception also help, though generally less than the IUD. Short courses of oral progesterone pills are actually the weakest studied option on this list. Procedures that remove or reduce the uterine lining, and ultimately hysterectomy, remain available as the last steps, with hysterectomy being the only option with a zero re-bleeding rate.
The debate is not about which treatment is most effective in isolation, but about how far up the ladder to start, whether conservative first-line treatment should always be tried first, or whether some women are better served moving to more definitive treatment sooner.
What the research shows, and which source each finding rests on
The hormone-releasing IUD is recommended first-line for heavy bleeding with no or small fibroids; users report blood-loss reductions of up to 90%, it lowered measured blood loss versus other medical therapy (mean difference 66.91 mL, moderate certainty), and women on other medical therapy were more likely to fail or withdraw from treatment (RR 0.34 favoring the IUD).
Tranexamic acid reduces mean blood loss by 53 mL per cycle versus placebo (moderate quality) and roughly triples the odds of improvement (RR 3.34); if 11% improve without treatment, 43-63% improve on tranexamic acid, and it is more effective than NSAIDs and oral luteal progestogens but may be less effective than the hormone-releasing IUD.
Short luteal-phase oral progesterone courses (7-10 days) are inferior to tranexamic acid, danazol, and the hormone-releasing IUD for reducing blood loss; long-cycle regimens are also inferior to the IUD and tranexamic acid.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Start conservative, escalate as needed
the treatment-ladder evidence and national guidance
Because five-year satisfaction is essentially the same whether a woman starts with the IUD or goes straight to hysterectomy, starting with the least invasive effective option loses nothing except, for some women, time, while sparing many from major surgery altogether.
Definitive treatment has real advantages for some women
the broader hysterectomy debate
Every conservative option carries a real failure or re-operation risk, and hysterectomy is the only treatment with a zero re-bleeding rate, so for some women, especially those with severe symptoms or who have already tried and failed conservative options, moving more directly to definitive treatment can be the more reasonable choice.
What would settle it: Not an unresolved research question; the informed preference of the individual woman, combined with her own assessment of symptom burden, is the legitimate tiebreaker at each rung of the ladder.
What is really going on here
- A common real-world prescribing pattern, a week of oral progesterone, is actually the weakest studied option for reducing blood-loss volume, worth asking your clinician directly why it was chosen over better-evidenced alternatives.
Questions for your doctor
- Where would you start me on the treatment ladder, and why?
- What would make you recommend moving to the next step, like ablation or hysterectomy?
- Is the hormone-releasing IUD an option for me given my anatomy and fibroid situation?
- If I try a conservative option first, does that limit my options later?
Questions with no answer yet
If a woman's IUD is ultimately going to fail and she'll need surgery anyway, does starting conservative first cost her extra years of symptoms even though her satisfaction at five years ends up the same?
Partly studiedWhat is known: Five-year satisfaction was essentially identical whether women started with the hormone-releasing IUD or went straight to hysterectomy, because women whose IUD failed could still cross over to surgery, and some IUD users cross over within the first year; the equal-satisfaction figure does not by itself show how many symptomatic months or years the crossover group experienced before switching.
What would test it: An analysis of time-to-relief or cumulative symptom burden, not just final satisfaction, comparing women who started with the IUD against those who went straight to surgery.
Among women who try tranexamic acid, NSAIDs, or combined hormonal contraception first, how do outcomes compare directly against each other, rather than each being compared only to placebo?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: Tranexamic acid, NSAIDs, and combined hormonal contraception have each been shown effective compared with placebo, and tranexamic acid is described as probably more effective than NSAIDs and oral luteal progestogens, but the evidence for these ladder comparisons is low to moderate quality, not head-to-head trials designed to compare the middle-of-the-ladder options directly against one another.
What would test it: A head-to-head randomized trial directly comparing tranexamic acid, NSAIDs, and combined hormonal contraception against each other rather than each against placebo separately.
Sources
- 1.Progestogen-releasing intrauterine systems for heavy menstrual bleeding.Bofill Rodriguez M, Lethaby A, Jordan V, Cochrane Database Syst Rev 2020;6:CD002126 · Systematic review or guideline
- 2.Antifibrinolytics for heavy menstrual bleeding.Bryant-Smith AC, Lethaby A, Farquhar C, Hickey M, Cochrane Database Syst Rev 2018;4:CD000249 · Systematic review or guideline
- 3.Cyclical progestogens for heavy menstrual bleeding.Bofill Rodriguez M et al., Cochrane Database Syst Rev 2019;8:CD001016 · Systematic review or guideline
- 4.Progestogen-releasing intrauterine systems for heavy menstrual bleeding.Bofill Rodriguez M et al., Cochrane Database Syst Rev 2020;6:CD002126 (Finnish LNG-IUS vs hysterectomy trial data) · Systematic review or guideline
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- What cycle changes are actually normal in perimenopause, and what's too much?
- What kind of bleeding during perimenopause means I should see a doctor right away?
- Is my fatigue actually from low iron, not perimenopause hormones?
- What ferritin level actually counts as iron deficient, I've heard 15, 30, and 50 all mentioned?
- When does heavy or abnormal bleeding actually need a biopsy?
- I had no periods for over a year and now I'm bleeding again, what does that mean?
- Back to topic: Cycle changes, bleeding red flags and iron